Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.
HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...
Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...
Japanese pharmaceutical company Daiichi Sankyo announced on Tuesday that Daiichi Sankyo and AstraZeneca's ENHERTU® has been granted conditional approval in China for the treatment of certain patients ...
Greenwich's $3.81 million cash position covers less than two months of operations, making near-term financing highly likely ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
AstraZeneca has announced a $15 billion investment in China through 2030 to expand research, development and manufacturing capabilities, supporting its long-term growth strategy and global pipeline in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results